European Medicines Agency Validates Bristol Myers Squibb蘑菇视频 Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

TAGGED : cancer

Calidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer蘑菇视频 38th Annual Meeting (SITC 2023)

November 3, 2023

SAN DIEGO--(BUSINESS WIRE)--Nov 3, 2023--Calidi Biotherapeutics, Inc. (NYSE American: CLDI or 鈥淐alidi鈥�), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the presentation of new preclinical data from the company蘑菇视频 CLD-201 ...

TC BioPharm Announces Streamlined Efficiencies and Reduces Overhead with Selection of Single Global CRO for Clinical Trials

November 3, 2023

<ul><li>Creates economic leverage with vertical integration of database and management</li></ul>EDINBURGH, Scotland, Nov. 2, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage ...

Innate Pharma Announces New Clinical Data for Lacutamab and SAR443579/IPH6101 at ASH 2023

November 3, 2023

MARSEILLE, France--(BUSINESS WIRE)--Nov 3, 2023--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (鈥� <em>Innate</em> 鈥� or the 鈥� <em>Company</em> 鈥�) today announced that several abstracts, including one oral presentation, have ...

VALUABLE NEW DATASET GIVES INSIGHT INTO LINKS AMONG PEDIATRIC CONDITIONS

November 2, 2023

PHILADELPHIA, Nov. 2, 2023 /PRNewswire/ -- The NIH Common Fund's Gabriella Miller Kids First Pediatric Research Program <a ...

First canine patient receives Vetigenics’ fully canine anti-CTLA4 monoclonal antibody for oral melanoma

November 2, 2023

Two fully funded pilot studies to treat cancer free for pet owners who bring their dogs to research sites.PHILADELPHIA, Nov. 2, 2023 /PRNewswire/ -- Vetigenics, a clinical-stage biopharmaceutical company advancing antibody-based therapies for pets, announces that the first canine patient with ...

Bayer and Broad Institute of MIT and Harvard Extend Research Collaboration to Develop New Cancer Therapies

November 2, 2023

BERLIN & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 2, 2023--Bayer and the Broad Institute of MIT and Harvard today announced that they have extended their research collaboration of 10 years by an additional five years, to develop and advance innovative cancer treatments. The expanded ...